ArticleFrontiers in oncology2025
Beneficial impact of indocyanine green fluorescence imaging on lymphadenectomy in laparoscopic total gastrectomy for advanced upper gastric cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to analyze the benefits of indocyanine green (ICG) fluorescence imaging on the efficacy of lymph node dissection (LND) during laparoscopic total gastrectomy (LTG) for advanced upper gastric cancer. Materials and methods: We retrospectively analyzed the clinicopathological data of 98 patients with advanced upper gastric cancer undergoing LTG, including 29 patients in the ICG-guided group and 69 in the conventional LTG (non-ICG) group. The perioperative outcomes, efficiency of LND, and survival outcomes were compared between the two groups. Results: The mean number of lymph nodes (LNs) dissected was greater in the ICG group than the non-ICG group (52.34 vs. 37.38; P < 0.001). Additionally, the ICG group had more patients with > 30 dissected LNs (96.55% vs. 76.81%; P = 0.018). Notably, the ICG group exhibited a higher number of LNs dissected at stations 7, 8, 9, and 11 than the non-ICG group (P < 0.05). Metastatic LNs were more frequently identified among fluorescence-positive LNs (P = 0.002). ICG fluorescence imaging demonstrated excellent diagnostic performance for metastatic LNs with a sensitivity of 85.9% and a negative predictive value of 96%. The ICG and non-ICG groups showed comparable 2-year overall survival (86.2% vs 82.6%, p=0.737) and disease-free survival (82.8% vs 72.5%, p=0.203) rates. Conclusions: ICG fluorescence imaging significantly improved lymphadenectomy precision during LTG for advanced upper gastric cancer, particularly in suprapancreatic nodal stations, and enhanced detection of metastatic LNs. However, no obvious survival benefit was observed within the limited follow-up period. Future prospective, multicenter studies are warranted to validate these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.